Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 13/2014

01-12-2014 | Gastrointestinal Oncology

The American Society of Peritoneal Surface Malignancies (ASPSM) Multiinstitution Evaluation of the Peritoneal Surface Disease Severity Score (PSDSS) in 1,013 Patients with Colorectal Cancer with Peritoneal Carcinomatosis

Authors: Jesus Esquivel, MD, Andrew M. Lowy, MD, Maurie Markman, MD, Terence Chua, MD, Joerg Pelz, MD, Dario Baratti, MD, Joel M. Baumgartner, MD, Richard Berri, MD, Pedro Bretcha-Boix, MD, Marcello Deraco, MD, Guillermo Flores-Ayala, MD, Olivier Glehen, MD, Alberto Gomez-Portilla, MD, Santiago González-Moreno, MD, Martin Goodman, MD, Evgenia Halkia, MD, Shigeki Kusamura, MD, Mecker Moller, MD, Guillaume Passot, MD, Marc Pocard, MD, George Salti, MD, Armando Sardi, MD, Maheswari Senthil, MD, John Spilioitis, MD, Juan Torres-Melero, MD, Kiran Turaga, MD, Richard Trout, PhD

Published in: Annals of Surgical Oncology | Issue 13/2014

Login to get access

ABSTRACT

Background

Extensive clinical experience suggests that hyperthermic intraperitoneal chemotherapy (HIPEC) may play an important role in the management of colorectal cancer patients with peritoneal carcinomatosis (CRCPC). However, there remains no established nonsurgical process to rationally select patients for this management, either for inclusion/stratification in clinical trials or as a component of standard of care. The Peritoneal Surface Disease Severity Score (PSDSS) was introduced as a basis to improve patient selection.

Methods

The American Society of Peritoneal Surface Malignancies conducted a retrospective review of 1,013 CRCPC patients. The PSDSS was evaluated on 3 specific criteria obtained before surgery (symptoms, extent of peritoneal dissemination, and primary tumor histology). Overall survival was analyzed according to four tiers of disease severity, and a comparison was made between patients who underwent cytoreductive surgery + HIPEC and those who did not.

Results

The PSDSS was calculated on 884 patients (87 %). The median survival of 275 patients not undergoing CRS/HIPEC based on their PSDSS—I (n = 8), II (n = 80), III (n = 55), and IV (n = 132)—was 45, 19, 8, and 6 months, respectively. The median survival of 609 patients who underwent CRS/HIPEC based on their PSDSS—I (n = 75), II (n = 317), III (n = 82), and IV (n = 135)—was 86, 43, 29, and 28 months, respectively.

Conclusions

These data support that the PSDSS, undertaken before surgery, is capable of defining CRCPC populations who have a statistically defined high or considerably lower likelihood of long-term survival after CRS/HIPEC. The PSDSS can be quite useful in the decision to enter CRCPC patients into, and their stratification within, clinical trials.
Literature
1.
Chu DZ, Lang NP, Thompson C, et al. Peritoneal carcinomatosis in nongynecological malignancy: a prospective study of prognostic factors. Cancer. 1989;63:364–367.PubMedCrossRef
2.
Jayne DG, Fook S, Loi C, et al. Peritoneal carcinomatosis from colorectal cancer. Br J Surg. 2002;89:1545–1550.PubMedCrossRef
3.
Sadeghi B, Arvieux C, Glehen O, et al. Peritoneal carcinomatosis from non-gynecological malignancies: results of the EVOCAPE 1 multicentric prospective study. Cancer. 2000;88:58–63.CrossRef
4.
Jacquet P, Vidal-Jove J, Zhu B, et al. Peritoneal carcinomatosis from gastrointestinal malignancy: natural history and new prospects for management. Acta Chir Belg. 1994;94:191–197.PubMed
5.
Glehen O, Kwiatkowski F, Sugarbaker PH, et al. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institution study. J Clin Oncol. 2004;22:3284–3292.PubMedCrossRef
6.
Elias D, Lefevre JH, Chevalier J, et al. Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. J Clin Oncol. 2009;27:681–685.PubMedCrossRef
7.
Chua TC, Esquivel J, Pelz JO, Morris DL. Summary of current therapeutic options for patients with peritoneal metastases from colorectal cancer. J Surg Oncol. 2013;107:566–573.PubMedCrossRef
8.
Yan TD, Black D, Savady R, et al. Systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal carcinoma. J Clin Oncol. 2006;24:4011–4019.PubMedCrossRef
9.
Pelz O, Stojadinovic A, Nissan A, Hohenberger W, Esquivel J. Evaluation of a Peritoneal Surface Disease Severity Score in patients with colon cancer and peritoneal dissemination. J Surg Oncol. 2009;99:9–15.PubMedCrossRef
10.
Chua TC, Morris DL, Esquivel J. Impact of the Peritoneal Surface Disease Severity Score on survival in patients with colorectal cancer peritoneal carcinomatosis undergoing complete cytoreduction and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2010;17:1330–1336.PubMedCrossRef
11.
Esquivel J, Chua T, Stojadinovic A, et al. Accuracy and clinical relevance of computed tomography scan interpretation of peritoneal cancer index in colorectal cancer peritoneal carcinomatosis: a multi-institutional study. J Surg Oncol. 2010;102:565–570.PubMedCrossRef
12.
Pelz JO, Chua TC, Esquivel J, et al. Evaluation of best supportive care and systemic chemotherapy as treatment stratified according to the retrospective Peritoneal Surface Disease Severity Score (PSDSS) for peritoneal carcinomatosis of colorectal origin. BMC Cancer. 2010;10:689.PubMedCentralPubMedCrossRef
13.
Franko J, Shi Q, Goldman CD, et al. Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pool analysis of North Central Cancer Treatment Group phase III trials N9741 and N9841. J Clin Oncol. 2012;30:263–267.PubMedCentralPubMedCrossRef
14.
Klaver YLB, Simkens LHJ, Lemmens VEPP, et al. Outcomes of colorectal cancer patients with peritoneal carcinomatosis treated with chemotherapy with and without targeted therapy. Eur J Surg Oncol. 2012;38:617–623.PubMedCrossRef
15.
Koopman M, Antonini NF, Douma J, et al. Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomized control trial. Lancet. 2007;370:135–142 .PubMedCrossRef
16.
Tol J, Koopman M, Rodenburg CJ, et al. A randomized phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO 2 study of the Dutch Colorectal Cancer Group. An interim analysis of toxicity. Ann Oncol. 2008;19:734–738.PubMedCrossRef
17.
Comprehensive molecular characterization of human colon and rectal cancer. The Cancer Genome Atlas Network. Nature. 2012;487:330–337.
18.
Van Cutsem E, Tabernero J, Lakomy R, et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol. 2012;30:3499–3506.PubMedCrossRef
19.
Turaga K, Levine E, Barone R, et al. Consensus guidelines from the American Society of Peritoneal Surface Malignancies on standardizing the delivery of hyperthermic intraperitoneal chemotherapy (HIPEC) in colorectal cancer patients in the united states. Ann Surg Oncol. 2014;21:1501–1505.PubMedCrossRef
Metadata
Title
The American Society of Peritoneal Surface Malignancies (ASPSM) Multiinstitution Evaluation of the Peritoneal Surface Disease Severity Score (PSDSS) in 1,013 Patients with Colorectal Cancer with Peritoneal Carcinomatosis
Authors
Jesus Esquivel, MD
Andrew M. Lowy, MD
Maurie Markman, MD
Terence Chua, MD
Joerg Pelz, MD
Dario Baratti, MD
Joel M. Baumgartner, MD
Richard Berri, MD
Pedro Bretcha-Boix, MD
Marcello Deraco, MD
Guillermo Flores-Ayala, MD
Olivier Glehen, MD
Alberto Gomez-Portilla, MD
Santiago González-Moreno, MD
Martin Goodman, MD
Evgenia Halkia, MD
Shigeki Kusamura, MD
Mecker Moller, MD
Guillaume Passot, MD
Marc Pocard, MD
George Salti, MD
Armando Sardi, MD
Maheswari Senthil, MD
John Spilioitis, MD
Juan Torres-Melero, MD
Kiran Turaga, MD
Richard Trout, PhD
Publication date
01-12-2014
Publisher
Springer US
Published in
Annals of Surgical Oncology / Issue 13/2014
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-014-3798-z

Other articles of this Issue 13/2014

Annals of Surgical Oncology 13/2014 Go to the issue

Endocrine Tumors

Failure of Radioactive Iodine in the Treatment of Hyperthyroidism

Thoracic Oncology

Homozygous GNAS 393C-Allele Carriers with Locally Advanced Esophageal Cancer Fail to Benefit from Platinum-Based Preoperative Chemoradiotherapy

Melanomas

International Multi-institutional Management and Outcome of Melanoma Patients with Positive Sentinel Lymph Nodes in More than One Nodal Basin

Head and Neck Oncology

Assessment of Erlotinib as Adjuvant Chemoprevention in High-Risk Head and Neck Cancer Patients

Gastrointestinal Oncology

Significance of Diaphragmatic Resections and Thoracic Chemoperfusion on Outcomes of Peritoneal Surface Disease Treated with Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC)

Hepatobiliary Tumors

Favorable Outcome After Repeat Resection for Colorectal Liver Metastases